What major milestone did PolyNovo (ASX:PNV) announce regarding its U.S. burn trial?

PolyNovo has finalised the Clinical Study Report (CSR) for its U.S. pivotal randomised controlled trial evaluating NovoSorb BTM on full-thickness burns. Backed by 12-month patient follow-up data, the report is a critical step toward securing an official on-label indication in the United States.

Why is PolyNovo (ASX:PNV) updating its Premarket Approval submission timeline?

The company is adjusting its strategy in response to new U.S. Food and Drug Administration (FDA) guidance regarding quality management system (QMS) information, which took effect in February.

How do the shifting FDA guidelines change PolyNovo’s initial submission strategy?

PolyNovo is bringing forward certain manufacturing and validation activities that were originally planned for after the submission. Including these operations early is designed to strengthen the initial package and maximise FDA inspection readiness.

When does PolyNovo (ASX:PNV) now expect to submit its full PMA application to the FDA?

Under the leadership of newly appointed Chief Quality & Regulatory Affairs Officer Allison Myers, PolyNovo projects full PMA submission before the end of calendar year 2026. The company is prioritising the comprehensive completion and documentation of key supplier and manufacturing processes to ensure a robust, review-ready filing.

Does the delayed submission timeline affect the overall FDA approval date for NovoSorb BTM?

No, the ultimate regulatory timeline remains unaffected because the altered approach allows PolyNovo to integrate 18-month patient follow-up data directly into the initial application. Since the FDA requires this 18-month data before granting a Premarket Approval anyway, bringing the validation work forward does not push back the final potential approval date.

What is the immediate impact of this timeline adjustment on PolyNovo’s current revenue and sales?

Management confirmed that the updated submission timeline has no material impact on current sales or revenue. NovoSorb products continue to be utilised by clinicians globally under existing regulatory approvals, and market demand for the product remains strong.

Image for illustrative purposes only. Not a real photo.

PolyNovo finalises US burn trial report

Written by Brie CarterPublished May. 29 2026Last Updated May. 29 2026

PolyNovo (ASX:PNV) has finalised the clinical study report for its US pivotal randomised controlled trial evaluating NovoSorb BTM for full-thickness burns.

Backed by 12-month patient follow-up data, the CSR marks a critical milestone towards securing an on-label indication in the United States, with funding support from the Biomedical Advanced Research and Development Authority.

In response to updated U.S. Food and Drug Administration guidance regarding quality management system information that took effect in February, PolyNovo has proactively refined its Premarket Approval submission strategy.

Following a comprehensive review of its submission plan, the company has reorganised the sequencing of its manufacturing and validation activities.

Certain operations originally scheduled for post-submission will now be brought forward to bolster the initial submission package, maximise inspection readiness, and meet shifting regulatory requirements.

This altered approach allows the company to integrate 18-month patient follow-up data directly into the final application. Because this long-term data is required before an approval can be granted, the overall FDA review timeline remains unaffected.

Under the guidance of newly appointed Chief Quality & Regulatory Affairs Officer Allison Myers, the medical device firm now projects full PMA submission before the conclusion of 2026.

At the time of reporting, PolyNovo’s share price was $1.23.